Business Overview: Foghorn Therapeutics Inc. (NASDAQ: FHTX)

---

Executive Summary

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, founded in 2015 by Flagship Pioneering together with academic co-founders Cigall Kadoch and Gerald Crabtree. Foghorn is built around a single proprietary drug discovery platform, which it calls Gene Traffic Control, aimed at targeting genetically determined dependencies in the chromatin regulatory system — the cellular machinery that controls which genes are switched on or off — starting with oncology.

Unlike a traditional biotech with one lead asset, Foghorn's business is the platform itself: a combination of genomic screening, AI/machine-learning-assisted target identification, large-scale production of chromatin regulatory protein complexes (such as the BAF complex), and targeted protein degradation chemistry, all aimed at drugging a class of cancer targets that have historically been considered difficult or "undruggable."

It matters because Foghorn has validated its platform commercially through major pharma partnerships — most notably a landmark collaboration with Eli Lilly — while still carrying the existential, binary risk profile common to all clinical-stage biotechs: its value depends almost entirely on whether its pipeline molecules eventually show efficacy and safety in human trials.

---

1. Core Business Model & How They Work

Foghorn does not yet sell any approved product. Its revenue today comes from upfront payments, milestones, and royalties from pharmaceutical partners who license access to its platform and co-develop specific drug candidates, supplemented by its own wholly-owned pipeline that it may eventually commercialize or out-license.

[ Gene Traffic Control Platform ] ➡️ [ Target ID (genomic screens + AI/ML) ] ➡️ [ Chromatin Complex Production at Scale ]
        ⬇️                                                                                      ⬇️
[ Partnered Programs (e.g., Eli Lilly) ]                                        [ High-Throughput Screening + Degrader/Inhibitor Chemistry ]
        ⬇️                                                                                      ⬇️
[ Upfront Cash + Milestones + Royalties ]  ➕  [ Wholly-Owned Pipeline ] ➡️ [ IND Filing ] ➡️ [ Clinical Trials ] ➡️ [ Approval / Partnership / Acquisition ]

Key Operational Drivers

1. Platform Licensing & Co-Development: Foghorn's 2021 collaboration with Eli Lilly (via Loxo Oncology) brought a $300 million upfront payment and an $80 million equity investment, with Foghorn eligible for up to $1.3 billion in milestones across co-developed and discovery programs — validating the platform's commercial value well before any drug reaches the market.
2. Wholly-Owned Pipeline Optionality: Programs such as selective CBP and EP300 degraders and an ARID1B degrader remain fully owned by Foghorn, preserving the potential for larger economics if they succeed.
3. Capital Discipline: Management has narrowed net losses through "tighter cost management and program prioritization," extending its cash runway into the first half of 2028 as of early 2026, aided by a $50 million registered direct financing.
4. Binary Clinical Risk: As with all clinical-stage biotechs, value creation depends on clinical trial results; most of the pipeline remains in Phase 1 or preclinical stages.

---

2. Business Segments

Foghorn operates as a single-segment clinical-stage biopharmaceutical company; it does not report distinct business segments. Its pipeline, however, breaks into two categories:

                         Foghorn Therapeutics Inc.
                                    |
                   Gene Traffic Control Platform (single business)
                                    |
                 ---------------------------------------------
                 |                                           |
     Partnered Programs (with Lilly)              Wholly-Owned Pipeline
   FHD-909 (LY4050784) - Phase 1, SMARCA4-       CBPd-171 (CBP degrader) - preclinical
   mutant NSCLC; additional discovery programs     Selective EP300 degrader - preclinical
                                                   Selective ARID1B degrader - preclinical

---

3. Product Portfolio (Pipeline)

---

4. Competitive Landscape

                High Platform Breadth (multi-target discovery engine)
                             |
   Foghorn Therapeutics ●    |
   (Gene Traffic Control)    |
                             |
Narrow Focus  ------------------------------- Broad Focus
                             |
   Smaller chromatin-biology  |    ● C4 Therapeutics, Arvinas (targeted protein
   specialists                |       degradation specialists)
                             |
                Low Platform Breadth

• C4 Therapeutics and Arvinas are the most direct competitors in targeted protein degradation, a chemistry approach Foghorn also uses for several of its chromatin-focused candidates.
• Large pharma oncology R&D organizations (e.g., Merck, Novartis, AstraZeneca) compete broadly in oncology drug discovery and could independently pursue chromatin-biology targets.
• In specific indications like AML, Foghorn's candidates would eventually compete with approved therapies such as Mylotarg, Rydapt, Idhifa, and Tibsovo.
• Foghorn's platform partnership model (licensing Gene Traffic Control to Lilly and Merck) differentiates it from degrader-focused peers that more often pursue solo clinical development.

---

5. Strategic Strengths & Risks

Strengths (Moat Sources)

1. Proprietary Platform Validated by Big Pharma: The $300 million upfront plus $80 million equity investment from Eli Lilly, and an earlier $15 million upfront collaboration with Merck, are concrete third-party validation of Foghorn's chromatin-biology discovery engine.
2. Deep, Narrow Technical Expertise: Co-founded by leading academic researchers in chromatin regulation (Cigall Kadoch, Gerald Crabtree), Foghorn has built specialized know-how in producing and screening against large chromatin regulatory complexes like BAF — technically difficult to replicate.
3. Capital Efficiency: Narrowing 2025 net losses to $74.3 million (from $86.6 million) and extending runway into H1 2028 shows disciplined management of a limited capital base.

Risks

1. Binary Clinical Risk: Nearly the entire pipeline is in Phase 1 or preclinical stages; a single trial failure (e.g., for lead asset FHD-909) could materially impair the company's value.
2. Platform Dependency: Virtually all value is tied to one scientific thesis (chromatin regulatory biology); if the underlying biology does not translate into durable clinical efficacy across multiple programs, the entire platform's worth is called into question.
3. Partner Concentration: A large share of near-term economics depends on continued collaboration decisions by Eli Lilly, giving Foghorn limited control over the pace and prioritization of its most advanced partnered asset.
4. Ongoing Cash Burn: Despite narrowing losses, Foghorn remains pre-revenue from product sales and will likely need further dilutive financing (as with the January 2026 $50 million raise) before any drug reaches commercialization.

---

6. Financial Overview

---

7. Summary Conclusion

Foghorn Therapeutics' moat is built on genuinely hard-to-replicate scientific expertise in chromatin regulatory biology, reinforced by concrete commercial validation from a major pharmaceutical partner in Eli Lilly. That is a real, if narrow, form of intangible-asset and technical-knowledge advantage rather than scale or network effects. The company's biggest forward risk remains the one common to all platform biotechs at this stage: clinical execution. With its lead partnered asset FHD-909 still in Phase 1 and most of its wholly-owned pipeline in preclinical stages, Foghorn's near-term cash runway buys time, but the ultimate test of whether chromatin-targeted therapies can become real medicines — and whether Foghorn captures a meaningful share of that value — is still ahead.